Please assess the completion status of the following clinical trial:

Trial Title: Evaluate the Efficacy and Safety of Pletaal (Cilostazol) in Subjects With Vasospastic Angina

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female over the age of 20 and under the age of 80~2. Diagnosis of vasospastic angina~3. At least one episode of chest pain weekly during the Amlodipine run in period for 2 weeks~Exclusion Criteria:~1. Currently taking or has taken Cilostazol within the last 3 month before the screening.~2. Taking oral antiplatelet agents such as Aspirin, Clopidogrel after Amlodipine run-in period.~3. Oral anticoagulants such as Warfarin within the last a month before the screening.~4. Currently taking any of the following medications or has taken any of the following medications within the last a week before the screening:~   * Other Calcium channel blockers than Amlodipine~  * Beta-blocker, or Alpha-blocker~  * Oral Nitrate, Nicorandil, except sublingual Nitroglycerin as required(PRN)~  * Vitamin E preparations~  * Estrogens~5. History of Myocardial infarction or Myocardial infarction by vasospastic angina at screening~6. History of life threatening vasospastic events such as ventricular tachycardia , ventricular fibrillation, or syncope~7. History of stroke, intracranial hemorrhage, or Transient Ischemic Attack(TIA)~8. Hemorrhage (hemophilia, capillary fragility, intracranial hemorrhage, upper gastrointestinal hemorrhage, urinary hemorrhage, hemoptysis, vitreous hemorrhage, etc.) or such tendency (active peptic ulcer, hemorrhagic stroke within past 6 months, a case hemorrhage is suspected by wound for surgery within 3 months, proliferative diabetic retinopathy and uncontrolled hypertension)~9. History of clinically significant hypersensitivity to the substances of Cilostazol, Amlodipine, Nitroglycerin or dihydropyridine~10. Patients with severe aortic valvular stenosis~11. History of shock~12. Hypotension of diastolic pressure \< 90 mmHg at screening~13. History of clinically significant hypersensitivity to the substances of Nitrates~14. Patients with severe anemia of Hemoglobin ≤ 6.5 g/dl at screening~15. History of glaucoma~16. Electrocardiogram(ECG) abnormality precluding interpretation of ST change at screening~17. Congestive heart failure with less than 40% of left ventricular ejection fraction within the last 3 month before the screening or screening period~18. Atrial fibrillation or valvular heart disease, more than moderate severity~19. Suspected or identified spasm of left main coronary artery, result of coronary angiography or coronary angiography in the ergonovine induced coronary spasm provocation test~20. History of Coronary artery bypass graft(CABG) or percutaneous coronary intervention(PCI)~21. Tachycardia; Heart rate \> 100 bpm, at Screening~22. Uncontrolled hypertension, defined as ≥ 160 mmHg systolic or ≥ 100 mmHg diastolic at Screening~23. Creatinine ≥ 1.5 mg/dL at screening~24. Aspartate transaminase (AST) or alanine transaminase (ALT) \> 3 times the upper limit of normal (ULN) at screening~25. Platelet \< 100,000 mm3 at screening~26. QT prolongation defined as baseline QTc \> 450 msec for males or \> 470 msec for females at Screening.~27. Women who have the possible of pregnancy, or positive urine or blood pregnancy test at screening~28. Women who are not using a reliable method of birth control, who are pregnant, or who are breast-feeding~29. Drug compliance of Amlodipine \< 80% during the Amlodipine run in period for 2 weeks~30. Otherwise judged by the investigator to be inappropriate for inclusion in the trial.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Cilostazol (Type: EXPERIMENTAL): To investigate the efficacy and safety of Pletaal(Cilostazol) in comparison with placebo for 4 weeks in vasospastic angina patients who have an insufficient response to Amlodipine (Calcium channel blocker).

Based on this trial design, predict the completion outcome and termination type (if applicable).